Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 5/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | CHRND | Q07001 | 5/20 | 0.49 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.49 |
| ▸ | CHRNG | P07510 | 1/20 | 0.49 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28031750 | 1.00 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| SCHEMBL620470 | 1.00 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| SCHEMBL7142929 | 1.00 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| SCHEMBL28663068 | 1.00 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| SCHEMBL8975007 | 1.00 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| SCHEMBL23778217 | 1.00 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| SCHEMBL28379862 | 1.00 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| SCHEMBL38651117 | 1.00 | GRIA1 (0.50) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| Hydrochloric Acid SCHEMBL906368 | 0.99 | GRIA1 (0.49) | GRIA1FOLH1CHRNDCHRNA1CHRNG | |
| Hydrochloric Acid SCHEMBL906366 | 0.99 | GRIA1 (0.49) | GRIA1FOLH1CHRNDCHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1585 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582711-B2 | RNA-based adjuvant to enhance the immune response to vaccines and therapeutics | ImmuneSure LLC (US) | 2026-03-24 | — | — | US | claimed |
| EP-4487869-A2 | RNA ENCODING A TUMOR ANTIGEN | CureVac SE (DE) | 2025-01-08 | — | — | EP | claimed |
| EP-2068918-B2 | VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT | ACCESS TO ADVANCED HEALTH INST (US) | 2024-07-03 | — | — | EP | claimed |
| EP-4324832-A2 | IMMUNOMODULATORY COMPOUNDS AND USE THEREOF FOR THE TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | AC BioScience SA (CH) | 2024-02-21 | — | — | EP | claimed |
| US-20230355749-A1 | Immunomodulatory Compounds And Use Thereof For The Treatment And/Or Prevention Of Infectious Diseases | AC BIOSCIENCE SA (CH) | 2023-11-09 | — | — | US | claimed |
| EP-4216997-A1 | IMMUNOMODULATORY COMPOUNDS AND USE THEREOF FOR THE TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | AC BioScience SA (CH) | 2023-08-02 | — | — | EP | claimed |
| US-20230165954-A1 | RNA-BASED ADJUVANT TO ENHANCE THE IMMUNE RESPONSE TO VACCINES AND THERAPEUTICS | ImmuneSure LLC | 2023-06-01 | — | — | US | claimed |
| US-11376325-B2 | Method of inducing an immune response using an expression construct and GLA | ACCESS TO ADVANCED HEALTH INSTITUTE (US) | 2022-07-05 | — | — | US | claimed |
| WO-2022063858-A1 | IMMUNOMODULATORY COMPOUNDS AND USE THEREOF FOR THE TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | AC BIOSCIENCE SA (CH) | 2022-03-31 | — | — | WO | claimed |
| EP-3973986-A1 | IMMUNOMODULATORY COMPOUNDS AND USE THEREOF FOR THE TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | AC BioScience SA (CH) | 2022-03-30 | — | — | EP | claimed |
| EP-0597838-A1 | VACCINE COMPOSITIONS | NORTH AMERICAN VACCINE, INC. (CA) | 1994-05-25 | — | — | EP | claimed |
| WO-1994005325-A1 | VACCINES AGAINST GROUP C NEISSERIA MENINGITIDIS | NORTH AMERICAN VACCINE, INC. (US) | 1994-03-17 | — | — | WO | claimed |
| EP-0549617-A1 | IMPROVED VACCINE COMPOSITIONS. | NORTH AMERICAN VACCINE INC (CA) | 1993-07-07 | — | — | EP | claimed |
| WO-1992004915-A1 | IMPROVED VACCINE COMPOSITIONS | NORTH AMERICAN VACCINE, INC. (CA) | 1992-04-02 | — | — | WO | claimed |
| WO-1991016926-A1 | VACCINE COMPOSITIONS | NORTH AMERICAN VACCINE, INC. (CA) | 1991-11-14 | — | — | WO | claimed |
| EP-0018189-B1 | SYNTHETIC ADJUVANTS FOR STIMULATING ANTIGENIC RESPONSES | CONNAUGHT LABORATORIES LIMITED (CA) | 1984-09-12 | — | — | EP | claimed |
| US-4428932-A | ALLERGY DESENSITIZATION | BEECHAM GROUP LIMITED (GB) | 1984-01-31 | — | — | US | claimed |
| EP-0064366-A1 | Pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1982-11-10 | — | — | EP | claimed |
| US-4258029-A | LONG CHAIN ALCOHOL ESTERS OF AMINO ACIDS | CONNAUGHT LABORATORIES LIMITED (CA) | 1981-03-24 | — | — | US | claimed |
| EP-0018189-A2 | Synthetic adjuvants for stimulating antigenic responses | CONNAUGHT LABORATORIES LIMITED (CA) | 1980-10-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376325-B2 | Method of inducing an immune response using an expression construct and GLA | TLR7, TLR3, TLR6 | GRIA1 654/4885FOLH1 2525/4885CHRND 3669/4885 |
| US-20230355749-A1 | Immunomodulatory Compounds And Use Thereof For The Treatment And/Or Prevention Of Infectious Diseases | CD14, TLR9, TLR3 | GRIA1 3490/4885FOLH1 3671/4885CHRND 3037/4885 |
| US-12582711-B2 | RNA-based adjuvant to enhance the immune response to vaccines and therapeutics | METTL16, RBM28, RBM26 | GRIA1 4551/4885FOLH1 1973/4885CHRND 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.